4
Changes in Ownership
SAB Biotherapeutics, Inc. Filed Acc 0001062993-23-021502
Director acquired 4,584,571 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. Director | 2023-11-24 | Option exercise | +4,584,571 | 4,584,571 | D | ||
| Derivatives | |||||||
| Sessa Capital (Master), L.P. Director | 2023-11-24 | Option exercise · Series A-1 Convertible Preferred Stock | −31,269 | $1,000.00 | $31,269,000 | 0 | D |
| Sessa Capital (Master), L.P. Director | 2023-11-24 | Option exercise · Series A-2 Convertible Preferred Stock | +28,380 | $1,000.00 | $28,380,000 | 28,380 | D |
Loading xslF345X05/form4.xml…